Oral News and Research

RSS

New data on diagnosis and treatment of allergic diseases to be presented at the ACAAI meeting

Researchers are unveiling new data on investigational findings in nearly 450 abstracts on the diagnosis and treatment of allergic diseases at the ACAAI Annual Meeting in Miami Beach, Fla., Nov. 5-10.

9 Nov 2009

Evaluation of DX-88 to resolve symptoms of acute HAE attacks to be presented

An analysis demonstrating the ability of DX-88 (ecallantide) to resolve symptoms of acute hereditary angioedema (HAE) attacks in all anatomic locations and to sustain effect will be presented in an oral presentation this week at the American College of Allergy, Asthma and Immunology (ACAAI) 2009 Annual Meeting in Miami Beach.

9 Nov 2009

Health experts report rising number of oral cancer in younger age groups

Mouth cancer (also called oral cancer) is a malignant growth which can occur in any part of the mouth including the lips and tongue. In the UK, the numbers of new cases have risen by over 41 per cent over the last ten years(1).

7 Nov 2009

Positive interim data from the multicenter randomized Phase II trial of palifosfamide presented

ZIOPHARM Oncology, Inc. presented today at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting, positive interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma.

6 Nov 2009

Data on Puredel's Ossulin to be presented at the San Francisco Diabetes Technology Meeting

The first public data on Ossulin™ a new oral insulin product, will be presented today at the 9th Annual Diabetes Technology Meeting in San Francisco, CA. Ossulin™ is being developed by Puredel Limited, a joint-venture between the European pharmaceutical specialty company CM&D Pharma Limited and Natreon Inc., New Brunswick, NJ., developers of the proprietary delivery platform.

6 Nov 2009

Novexel commences comparative study of NXL103 to oral linezolid

Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI). The trial is designed to assess the safety and efficacy of NXL103 in comparison to oral linezolid.

6 Nov 2009

Dentists can play a live-saving role by identifying patients at risk of fatal heart attacks: Study

A new study indicates dentists can play a potentially life-saving role in health care by identifying patients at risk of fatal heart attacks and referring them to physicians for further evaluation.

6 Nov 2009

CPEX Pharmaceuticals to feature Nasulin at the Diabetes Technology Meeting

CPEX Pharmaceuticals, Inc. today announced that its intranasal insulin product candidate, NasulinTM, will be featured in an oral presentation and four abstracts at the Ninth Annual Diabetes Technology Meeting, November 5-7, 2009 at the Hyatt Regency Airport in San Francisco, California.

6 Nov 2009

USPTO issues Notice of Allowance to NovaDel Pharma

NovaDel Pharma Inc., today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. Patent Application No. 10/671,715, entitled “Buccal, Polar and Non-polar Spray Containing Zolpidem,” which covers a method of treating insomnia by administering zolpidem to humans utilizing NovaMist™ Oral Spray spray technology.

6 Nov 2009

Rice University's new BRC awarded $2M NIH grant to develop an inexpensive test for oral cancer

The National Institutes of Health (NIH) has awarded researchers in Rice University's new BioScience Research Collaborative (BRC) a $2 million Grand Opportunity (GO) grant to develop a fast, inexpensive test for oral cancer that a dentist could perform simply by using a brush to collect a small sample of cells from a patient's mouth.

6 Nov 2009

Catalent Pharma Solutions, Endotis Pharma forge alliance to develop oral formulations of small-glycol drugs

Catalent Pharma Solutions, the leading provider of advanced oral drug delivery technologies to the pharmaceutical industry, has entered into a strategic alliance with Endotis Pharma for the development of oral formulations of synthetic oligosaccharides.

5 Nov 2009

FDA and FSIS announce joint public meeting to prevent foodborne illness

A joint public meeting focused on improving the system for tracing of food products and ingredients that are causing illness outbreaks or presenting other risks to the health of consumers was announced today by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services and the Food Safety and Inspection Service (FSIS) of the U.S. Department of Agriculture (USDA).

5 Nov 2009

Environmental Tectonics bags two new contracts worth $700,000 from previous customers

Environmental Tectonics Corporation's Sterilization Systems Group (SSG), a division of ETC's Control Systems Group (CSG), today announced the award of two new contracts for large, industrial sized sterilization systems from previous customers. The combined contract values exceed $700,000.

5 Nov 2009

ARIAD Pharmaceuticals' SUCCEED trial of oral ridaforolimus on track

ARIAD Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009 and provided an update on corporate developments.

5 Nov 2009

Dietary options and better detection improve food allergy management procedures

Less restrictive dietary options, better detection, targeted avoidance measures, educational directives and potential new therapies are improving food allergy management and giving hope to the more than 12 million Americans affected according to experts at the thirteenth international food allergy conference held during the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Miami Beach, Fla.

5 Nov 2009

Middlebrook Pharmaceuticals announces financial and operational results for third quarter 2009

MiddleBrook Pharmaceuticals, Inc. today announced its financial and operational results for the quarter ended Sept. 30, 2009.

5 Nov 2009

Study finds oral dimercaptosuccinic acid effective in treating children with autism

Two studies published by the Southwest College of Naturopathic Medicine in the October issue of BMC Clinical Pharmacology investigated the use of oral dimercaptosuccinic acid (DMSA), a prescription medicine approved by the FDA for treating lead poisoning, and used off-label in these studies for treating heavy metal toxicity in children with autism.

5 Nov 2009

Evidence continues to grow about green tea's cancer prevention properties

Although scientists are reluctant to officially endorse green tea as a cancer prevention method, evidence continues to grow about its protective effects, including results of a new study published in Cancer Prevention Research, a journal of the American Association for Cancer Research, which suggests some reduction in oral cancer.

5 Nov 2009

Employers sign up for first-of-its-kind health plan to control escalating health care costs

Employers are signing up for a first-of-its-kind health plan by UnitedHealthcare designed to help control the escalating costs of insuring diabetic and pre-diabetic employees and their families while improving their health.

5 Nov 2009

Green tea holds hope for prevention of oral cancer

Green tea extract has shown promise as cancer prevention agent for oral cancer in patients with a pre-malignant condition known as oral leukoplakia, according to researchers at The University of Texas M. D. Anderson Cancer Center.

5 Nov 2009

Oral News and Research

New data on diagnosis and treatment of allergic diseases to be presented at the ACAAI meeting

Evaluation of DX-88 to resolve symptoms of acute HAE attacks to be presented

Health experts report rising number of oral cancer in younger age groups

Positive interim data from the multicenter randomized Phase II trial of palifosfamide presented

Data on Puredel's Ossulin to be presented at the San Francisco Diabetes Technology Meeting

Novexel commences comparative study of NXL103 to oral linezolid

Dentists can play a live-saving role by identifying patients at risk of fatal heart attacks: Study

CPEX Pharmaceuticals to feature Nasulin at the Diabetes Technology Meeting

USPTO issues Notice of Allowance to NovaDel Pharma

Rice University's new BRC awarded $2M NIH grant to develop an inexpensive test for oral cancer

Catalent Pharma Solutions, Endotis Pharma forge alliance to develop oral formulations of small-glycol drugs

FDA and FSIS announce joint public meeting to prevent foodborne illness

Environmental Tectonics bags two new contracts worth $700,000 from previous customers

ARIAD Pharmaceuticals' SUCCEED trial of oral ridaforolimus on track

Dietary options and better detection improve food allergy management procedures

Middlebrook Pharmaceuticals announces financial and operational results for third quarter 2009

Study finds oral dimercaptosuccinic acid effective in treating children with autism

Evidence continues to grow about green tea's cancer prevention properties

Employers sign up for first-of-its-kind health plan to control escalating health care costs

Green tea holds hope for prevention of oral cancer

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News